INSM · Insmed Incorporated
$104.73
-0.57% last session
End-of-day data · updated 2026-07-29
Market cap
$23B
Enterprise value
$22B
Trailing P/E
—
Forward P/E
811.7
Dividend yield
—
Beta
0.78
Avg volume
4M
Employees
2K
2D change
-0.57%
5D change
-2.61%
10D change
-3.87%
30D change
-0.58%
60D change
-2.60%
MTD change
-2.68%
YTD change
-40.17%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — INSM
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-21
Latest call per bank · past 12 months
Wells Fargo
Overweight$161
+53.7% vs priceJP Morgan
Overweight$179
+70.9% vs priceRBC Capital
Outperform$195
+86.2% vs priceBarclays
Overweight$237
+126.3% vs priceMorgan Stanley
Overweight$212
+102.4% vs priceBank of America
Buy$213
+103.4% vs priceUBS
Buy$215
+105.3% vs priceGoldman Sachs
Buy$225
+114.8% vs priceJefferies
Buy$148
+41.3% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-21 | BMO Capital | Initiates | Outperform | $0.00 → $192 |
| 2026-07-15 | Wells Fargo | Maintains | Overweight | $160 → $161 |
| 2026-07-10 | Guggenheim | Reiterates | Buy | $207 |
| 2026-06-22 | Evercore ISI Group | Maintains | Outperform | $162 → $160 |
| 2026-06-08 | JP Morgan | Maintains | Overweight | $180 → $179 |
| 2026-06-05 | RBC Capital | Maintains | Outperform | $205 → $195 |
| 2026-05-14 | Truist Securities | Maintains | Buy | $205 → $185 |
| 2026-05-08 | RBC Capital | Maintains | Outperform | $220 → $205 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 43 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 1.1% below the 50-day MA ($105.29).
- Price vs 200-day MA: Trading 29.9% below the 200-day MA ($148.54).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is negative (-0.69) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($91.88) and high ($211.41).
INSM Price Chart
Loading chart for INSM…
Fundamentals
About Insmed Incorporated
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops INS1201, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as it is also developing pre-clinical research programs for gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. In addition, it provides INS1148, monoclonal antibody targeting stem cell factor called SCF248 that is in phase-2 clinical trial for the treatment of interstitial lung disease, and asthma; and INS1202, an intrathecally delivered gene therapy which is in phase 1 of clinical trial for the treatment of amyotrophic lateral sclerosis. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$124B 8.2% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$73B -9.7% YTD
ARGX
argenx SE
$55B 3.7% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$39B -27.5% YTD
RVMD
Revolution Medicines, Inc.
$39B 130.8% YTD
RPRX
Royalty Pharma plc
$35B 56.7% YTD
ONC
BeOne Medicines Ltd.
$34B 8.8% YTD
INCY
Incyte Corporation
$26B 31.6% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.